HLS Therapeutics Inc. (OTCMKTS:HLTRF) Short Interest Down 9.1% in March

HLS Therapeutics Inc. (OTCMKTS:HLTRF) was the recipient of a large drop in short interest during the month of March. As of March 31st, there was short interest totalling 2,000 shares, a drop of 9.1% from the March 15th total of 2,200 shares. Based on an average daily trading volume, of 100 shares, the short-interest ratio is currently 20.0 days.

HLS Therapeutics Stock Performance

HLTRF remained flat at $3.85 during trading on Wednesday. 102 shares of the company’s stock traded hands, compared to its average volume of 1,200. HLS Therapeutics has a 12 month low of $2.60 and a 12 month high of $4.95. The business has a fifty day moving average of $3.25 and a 200-day moving average of $3.35.

Analyst Ratings Changes

Separately, Raymond James decreased their target price on HLS Therapeutics from $6.50 to $5.00 and set a “market perform” rating for the company in a research report on Monday, March 18th.

HLS Therapeutics Company Profile

HLS Therapeutics Inc, a specialty pharmaceutical company, acquires and commercializes pharmaceutical products in the specialty central nervous system and cardiovascular markets in Canada, the United States, and internationally. The company's product portfolio includes Clozaril, an atypical antipsychotic for management of symptoms of treatment-resistant schizophrenia; and Vascepa, an icosapent ethyl capsules for cardiovascular disease.